Alder Biopharma (ALDR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2015 | 06-2015 | 03-2015 | 12-2014 | 09-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -59,305 | -32,308 | -14,653 | 8,908 | 15,850 |
| Depreciation Amortization | 571 | 385 | 195 | 701 | 527 |
| Accounts receivable | 113 | 113 | 113 | 203 | 235 |
| Accounts payable and accrued liabilities | 5,822 | 443 | 305 | -312 | -539 |
| Other Working Capital | 35 | -4,868 | -2,503 | -58,518 | -52,751 |
| Other Operating Activity | -1,802 | 1,752 | 494 | 1,361 | 1,062 |
| Operating Cash Flow | $-54,566 | $-34,483 | $-16,049 | $-47,657 | $-35,616 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -722 | -646 | -375 | -649 | -408 |
| Purchase Of Investment | -180,500 | -19,750 | -12,750 | -11,045 | -10,046 |
| Sale Of Investment | 15,355 | 8,390 | 1,475 | 1,960 | 0 |
| Investing Cash Flow | $-165,867 | $-12,006 | $-11,650 | $-9,734 | $-10,454 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 407,629 | 407,652 | 190,792 | 81,018 | 80,393 |
| Other Financing Activity | 36 | 36 | 36 | -36 | 0 |
| Financing Cash Flow | $407,665 | $407,688 | $190,828 | $80,982 | $80,393 |
| Exchange Rate Effect | -20 | -28 | -14 | -23 | 3 |
| Beginning Cash Position | 46,795 | 46,795 | 46,795 | 23,227 | 23,227 |
| End Cash Position | 234,007 | 407,966 | 209,910 | 46,795 | 57,553 |
| Net Cash Flow | $187,212 | $361,171 | $163,115 | $23,568 | $34,326 |
| Free Cash Flow | |||||
| Operating Cash Flow | -54,566 | -34,483 | -16,049 | -47,657 | -35,616 |
| Capital Expenditure | -722 | -646 | -375 | -649 | -408 |
| Free Cash Flow | -55,288 | -35,129 | -16,424 | -48,306 | -36,024 |